Lucy O. Day's most recent trade in AN2 Therapeutics Inc was a trade of 93,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 93,000 | 93,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Feb 2025 | 46,500 | 79,170 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 1.34 per share. | 03 Jan 2025 | 2,957 | 32,670 | - | 1.3 | 3,965 | Common Stock |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 55,000 | 55,000 | - | - | Stock Option (right to buy) | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Mar 2024 | 27,500 | 30,627 | - | 0 | Common Stock | |
| AN2 Therapeutics Inc | Lucy O. Day | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Feb 2023 | 82,300 | 82,300 | - | - | Stock Option (right to buy) |